Tesamorelin 10mg
$89.00
Tesamorelin is a synthetic peptide analogue of growth hormone–releasing hormone (GHRH), composed of 44 amino acids with a structural modification that enhances its stability and half-life. Although it has gained regulatory approval as Egrifta® for the treatment of HIV-associated lipodystrophy, tesamorelin is also widely investigated in the broader research context.
$89.00
$89.00
Peptide Capsules
Purchase Peptides
Purchase Blends
Tesamorelin is a synthetic peptide drug composed of 44 amino acids. It is an analogue of the naturally occurring growth hormone–releasing hormone (GHRH), which is responsible for stimulating the pituitary gland to release growth hormone (GH). To increase its stability and effectiveness, tesamorelin is chemically modified by attaching a trans-3-hexenoic acid group. This modification gives it a longer half-life compared to natural GHRH and makes it clinically useful.
Tesamorelin is currently FDA-approved under the brand name Egrifta (and its newer formulation, Egrifta SV/WR). Its primary use is for treating HIV-associated lipodystrophy, a condition in which patients living with HIV accumulate unhealthy amounts of visceral adipose tissue (VAT), which is the deep abdominal fat that surrounds internal organs.
This type of fat is particularly dangerous because it is associated with increased risks of cardiovascular disease, insulin resistance, and liver problems. Clinical studies have shown that tesamorelin can reduce VAT by approximately 15–20% over a treatment course of 6–12 months, with minimal effects on subcutaneous fat, which is the fat under the skin.
Tesamorelin : Structure
Sequence (Single Letter): Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C₂₂₃H₃₇₀N₇₂O₆₈S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6
Source:
Tesamorelin: Research
Growth Hormone & HIV
Treatment with highly active antiretroviral therapy (HAART) has improved survival in individuals with HIV but is linked to various endocrine and metabolic complications. One important area affected is the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis. Research shows that many HIV-positive patients, particularly those with HIV-associated lipodystrophy, exhibit impaired GH secretion and, in some cases, biochemical GH deficiency (GHD).
Both spontaneous GH release and responses to stimulation tests are reduced, with abnormal fat distribution playing a significant role in blunted secretion. However, the underlying mechanisms are complex and involve an interplay of HIV infection itself, HAART exposure, comorbidities, and changes in body composition.
Because of these disruptions, interest has grown in therapeutic approaches targeting the GH/IGF-1 pathway. Tesamorelin, a synthetic analogue of GHRH, has been shown to significantly reduce visceral adipose tissue in HIV patients with lipodystrophy. Compared to direct treatment with recombinant GH, tesamorelin is considered more effective and associated with a lower risk of side effects, making it a promising therapeutic option.
Lipodystrophy
Tesamorelin is a synthetic analogue of growth hormone–releasing hormone that promotes the natural release of growth hormone. It is currently the only approved therapy for reducing excess abdominal fat in people with HIV-associated lipodystrophy.
Clinical trials lasting 26 weeks demonstrated that subcutaneous tesamorelin effectively reduced visceral adipose tissue (VAT) without significantly altering subcutaneous fat. In patients who continued treatment through a 52-week extension, reductions in VAT were maintained, whereas those who stopped therapy experienced fat reaccumulation.
Beyond VAT reduction, tesamorelin improved additional body composition measures such as trunk fat and waist circumference, and patients reported better body image outcomes, including reduced distress over abdominal appearance.
The treatment was generally well tolerated. Fewer than 4% of participants experienced serious adverse events during the studies, with most side effects being injection-site reactions or symptoms already known from growth hormone therapies (such as joint pain, headache, and fluid retention).
While more long-term data are needed to fully confirm its safety and effectiveness, current evidence indicates tesamorelin is a valuable option for managing visceral fat accumulation and body image concerns in HIV-associated lipodystrophy.
Peripheral nerve damage
Peripheral nerve injuries are frequently associated with profound motor and sensory dysfunction. Despite advances in microsurgical repair techniques, no pharmacological agents are currently available in clinical practice to enhance the intrinsic regenerative process. Following surgical reconstruction, axons are often required to regenerate across substantial distances before reaching their distal targets. During this prolonged period, progressive atrophy of denervated skeletal muscle and Schwann cells (SCs) within the distal nerve segment significantly diminishes the likelihood of successful functional recovery. Therapeutic strategies based on growth hormone (GH) have emerged as a promising avenue, with the potential to accelerate axonal regrowth while simultaneously preserving the integrity of muscle tissue and the distal regenerative environment prior to reinnervation.
Referenced Citations
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products available on this website are intended solely for in-vitro research purposes (Latin: “in glass”), meaning they are used in experiments conducted outside a living organism. These products are not medicines or drugs, have not been evaluated or approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, treat, cure, or prevent any disease or medical condition. Any administration to humans or animals, whether by ingestion, injection, or other means, is strictly prohibited by law.
Test
Storage Instructions:
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below: